Expert review of anticancer therapy · 2025
Desmoid tumor control with liposomal doxorubicin: a dual-center retrospective analysis.
СтатьяМногоцентровое исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wytiaz Victoria, Dorand Rodney Dixon, Cohen Sean, Keedy Vicki Leigh, Borinstein Scott C, Schuetze Scott, Chugh Rashmi, Davis Elizabeth J
Аннотация
BACKGROUND: Desmoid tumors are rare, locally aggressive tumors that are often life-affecting with a significant burden on afflicted patients. While systemic therapy for progressive disease is often preferred, there is a paucity of studies comparing disease control rates of agents based on tumor location or other disease-related factors.
METHODS: Dual-center retrospective analysis of disease control in patients with intra-abdominal (IA) and extra-abdominal (EA) desmoid tumors who received liposomal doxorubicin (LD). Disease control rate (DCR) was defined as stable disease (if evidence of progression prior to LD therapy) or partial response.
RESULTS: 54 patients were included, 38.9% (21/54) with IA desmoid tumors and 35.2% (19/54) with Familial Adenomatous Polyposis (FAP)-associated desmoid tumors. DCRs for patients with IA and EA desmoid tumors were 76.2% and 45.5%, respectively (odds ratio 3.80; p = 0.03). The DCR for patients with FAP-associated desmoid tumors was 73.7%, compared to 48.6% for those without FAP (odds ratio 2.96, p = 0.09). Mean times to next treatment were 80.5 weeks and 36.3 weeks for patients with and without FAP.
CONCLUSION: LD is effective and well-tolerated with a high potential for tumor control and prolonged duration of time until next treatment, especially in patients with FAP and IA desmoid tumors.
METHODS: Dual-center retrospective analysis of disease control in patients with intra-abdominal (IA) and extra-abdominal (EA) desmoid tumors who received liposomal doxorubicin (LD). Disease control rate (DCR) was defined as stable disease (if evidence of progression prior to LD therapy) or partial response.
RESULTS: 54 patients were included, 38.9% (21/54) with IA desmoid tumors and 35.2% (19/54) with Familial Adenomatous Polyposis (FAP)-associated desmoid tumors. DCRs for patients with IA and EA desmoid tumors were 76.2% and 45.5%, respectively (odds ratio 3.80; p = 0.03). The DCR for patients with FAP-associated desmoid tumors was 73.7%, compared to 48.6% for those without FAP (odds ratio 2.96, p = 0.09). Mean times to next treatment were 80.5 weeks and 36.3 weeks for patients with and without FAP.
CONCLUSION: LD is effective and well-tolerated with a high potential for tumor control and prolonged duration of time until next treatment, especially in patients with FAP and IA desmoid tumors.